Liabilities and Equity of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly Liabilities and Equity in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Liabilities and Equity for the quarter ending 31 Dec 2025 was $25,643,000,000, a 14% increase year-over-year.
Source SEC data
View on sec.gov
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $25,643,000,000 +$3,109,800,000 +14% 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $24,862,300,000 +$2,622,100,000 +12% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $24,036,700,000 +$3,904,600,000 +19% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $22,880,500,000 -$1,036,900,000 -4.3% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $22,533,200,000 -$197,000,000 -0.87% 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $22,240,200,000 +$514,000,000 +2.4% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $20,132,100,000 -$217,100,000 -1.1% 30 Jun 2024 10-Q 02 Aug 2024 2024 Q2
Q1 2024 $23,917,400,000 +$4,943,200,000 +26% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $22,730,200,000 +$4,579,300,000 +25% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $21,726,200,000 +$5,019,800,000 +30% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $20,349,200,000 +$4,767,000,000 +31% 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $18,974,200,000 +$4,718,100,000 +33% 31 Mar 2023 10-Q 02 May 2023 2023 Q1
Q4 2022 $18,150,900,000 +$4,718,400,000 +35% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $16,706,400,000 +$4,087,655,000 +32% 30 Sep 2022 10-Q 28 Oct 2022 2022 Q3
Q2 2022 $15,582,200,000 +$3,360,514,000 +27% 30 Jun 2022 10-Q 05 Aug 2022 2022 Q2
Q1 2022 $14,256,100,000 +$2,141,041,000 +18% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $13,432,500,000 +$1,680,700,000 +14% 31 Dec 2021 10-K 10 Feb 2023 2022 FY
Q3 2021 $12,618,745,000 +$1,317,112,000 +12% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $12,221,686,000 +$2,005,319,000 +20% 30 Jun 2021 10-Q 30 Jul 2021 2021 Q2
Q1 2021 $12,115,059,000 +$3,221,858,000 +36% 31 Mar 2021 10-Q 30 Apr 2021 2021 Q1
Q4 2020 $11,751,800,000 +$3,433,335,000 +41% 31 Dec 2020 10-K 09 Feb 2022 2021 FY
Q3 2020 $11,301,633,000 +$3,787,080,000 +50% 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q2 2020 $10,216,367,000 +$3,182,896,000 +45% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $8,893,201,000 +$2,350,087,000 +36% 31 Mar 2020 10-Q 01 May 2020 2020 Q1
Q4 2019 $8,318,465,000 +$2,072,567,000 +33% 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $7,514,553,000 +$2,893,713,000 +63% 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $7,033,471,000 +$2,698,085,000 +62% 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $6,543,114,000 +$2,590,140,000 +66% 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $6,245,898,000 +$2,699,884,000 +76% 31 Dec 2018 10-K 13 Feb 2020 2019 FY
Q3 2018 $4,620,840,000 +$1,422,515,000 +44% 30 Sep 2018 10-Q 25 Oct 2018 2018 Q3
Q2 2018 $4,335,386,000 +$1,049,792,000 +32% 30 Jun 2018 10-Q 26 Jul 2018 2018 Q2
Q1 2018 $3,952,974,000 +$1,006,271,000 +34% 31 Mar 2018 10-Q 27 Apr 2018 2018 Q1
Q4 2017 $3,546,014,000 +$649,227,000 +22% 31 Dec 2017 10-K 13 Feb 2019 2018 FY
Q3 2017 $3,198,325,000 +$588,684,000 +23% 30 Sep 2017 10-Q 30 Oct 2017 2017 Q3
Q2 2017 $3,285,594,000 +$736,612,000 +29% 30 Jun 2017 10-Q 28 Jul 2017 2017 Q2
Q1 2017 $2,946,703,000 +$458,797,000 +18% 31 Mar 2017 10-Q 28 Apr 2017 2017 Q1
Q4 2016 $2,896,787,000 +$398,200,000 +16% 31 Dec 2016 10-K 15 Feb 2018 2017 FY
Q3 2016 $2,609,641,000 +$175,648,000 +7.2% 30 Sep 2016 10-Q 31 Oct 2016 2016 Q3
Q2 2016 $2,548,982,000 +$174,909,000 +7.4% 30 Jun 2016 10-Q 01 Aug 2016 2016 Q2
Q1 2016 $2,487,906,000 +$322,079,000 +15% 31 Mar 2016 10-Q 03 May 2016 2016 Q1
Q4 2015 $2,498,587,000 +$163,908,000 +7% 31 Dec 2015 10-K 23 Feb 2017 2016 FY
Q3 2015 $2,433,993,000 +$27,907,000 +1.2% 30 Sep 2015 10-Q 30 Oct 2015 2015 Q3
Q2 2015 $2,374,073,000 +$256,253,000 +12% 30 Jun 2015 10-Q 04 Aug 2015 2015 Q2
Q1 2015 $2,165,827,000 -$31,281,000 -1.4% 31 Mar 2015 10-Q 04 May 2015 2015 Q1
Q4 2014 $2,334,679,000 +$15,638,000 +0.67% 31 Dec 2014 10-K 16 Feb 2016 2015 FY
Q3 2014 $2,406,086,000 -$176,662,000 -6.8% 30 Sep 2014 10-Q 06 Nov 2014 2014 Q3
Q2 2014 $2,117,820,000 -$466,509,000 -18% 30 Jun 2014 10-Q 31 Jul 2014 2014 Q2
Q1 2014 $2,197,108,000 -$195,126,000 -8.2% 31 Mar 2014 10-Q 05 May 2014 2014 Q1
Q4 2013 $2,319,041,000 -$440,247,000 -16% 31 Dec 2013 10-K 13 Feb 2015 2014 FY
Q3 2013 $2,582,748,000 -$136,075,000 -5% 30 Sep 2013 10-Q 07 Nov 2013 2013 Q3
Q2 2013 $2,584,329,000 -$20,527,000 -0.79% 30 Jun 2013 10-Q 02 Aug 2013 2013 Q2
Q1 2013 $2,392,234,000 +$46,391,000 +2% 31 Mar 2013 10-Q 08 May 2013 2013 Q1
Q4 2012 $2,759,288,000 +$555,008,000 +25% 31 Dec 2012 10-K 11 Feb 2014 2013 FY
Q3 2012 $2,718,823,000 +$626,825,000 +30% 30 Sep 2012 10-Q 06 Nov 2012 2012 Q3
Q2 2012 $2,604,856,000 +$841,756,000 +48% 30 Jun 2012 10-Q 08 Aug 2012 2012 Q2
Q1 2012 $2,345,843,000 +$807,356,000 +52% 31 Mar 2012 10-Q 10 May 2012 2012 Q1
Q4 2011 $2,204,280,000 +$478,834,000 +28% 31 Dec 2011 10-K 01 Mar 2013 2012 FY
Q3 2011 $2,091,998,000 +$203,169,000 +11% 30 Sep 2011 10-Q 03 Nov 2011 2011 Q3
Q2 2011 $1,763,100,000 +$108,898,000 +6.6% 30 Jun 2011 10-Q 09 Aug 2011 2011 Q2
Q1 2011 $1,538,487,000 -$231,815,000 -13% 31 Mar 2011 10-Q 06 May 2011 2011 Q1
Q4 2010 $1,725,446,000 31 Dec 2010 10-K 22 Feb 2012 2011 FY
Q3 2010 $1,888,829,000 30 Sep 2010 10-Q 28 Oct 2010 2010 Q3
Q2 2010 $1,654,202,000 30 Jun 2010 10-Q 03 Aug 2010 2010 Q2
Q1 2010 $1,770,302,000 31 Mar 2010 10-Q 03 May 2010 2010 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.